Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae

Journal of Virology

Volumn 84, Issue 5, 2010, Pages 2511-2521

  O'Keefe, Barry R ^a   Giomarelli, Barbara ^a   Barnard, Dale L ^b   Shenoy, Shilpa R ^c   Chan, Paul K S ^d   McMahon, James B ^a   Palmer, Kenneth E ^e,f   Barnett, Brian W ^e   Meyerholz, David K ^g   Wohlford Lenane, Christine L ^g   McCray Jr , Paul B ^g  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UTAH STATE UNIVERSITY   (United States)

^c SAIC FREDERICK INC   (United States)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e University of Louisville School of Medicine   (United States)

^f Owensboro Cancer Research Program   (United States)

^g UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; PROTEIN GRIFFITHSIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME;

ALGAL PROTEINS; AMINO ACID SEQUENCE; ANIMALS; ANTIVIRAL AGENTS; CALORIMETRY; CELL LINE; CORONAVIRIDAE; CORONAVIRIDAE INFECTIONS; CYTOKINES; FEMALE; HUMANS; LECTINS; LUNG; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN CONFORMATION; SARS VIRUS; VIRAL ENVELOPE PROTEINS; ZOONOSES;

AVES; CORONAVIRIDAE; MAMMALIA; RNA VIRUSES; SARS CORONAVIRUS;

EID: 77649208121     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02322-09     Document Type: Article

References (38)

1. Barnard, D. L., C. W. Day, K. Bailey, M. Heiner, R. Montgomery, L. Lauridsen, P. K. Chan, and R. W. Sidwell. 2006. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. Antivir. Chem. Chemother. 17:275-284.
2. Blanchard, J. E., N. H. Elowe, C. Huitema, P. D. Fortin, J. D. Cechetto, L. D. Eltis, and E. D. Brown. 2004. High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase. Chem. Biol. 11:1445-1453.
3. Bosch, B. J., B. E. Martina, R. Van Der Zee, J. Lepault, B. J. Haijema, C. Versluis, A. J. Heck, R. De Groot, A. D. Osterhaus, and P. J. Rottier. 2004. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc. Natl. Acad. Sci. U. S. A. 101:8455-8460.
4. Cavanaugh, P. F., Jr., P. S. Moskwa, W. H. Donish, P. J. Pera, D. Richardson, and A. P. Andrese. 1990. A semi-automated neutral red based chemosensitivity assay for drug screening. Invest. New Drugs 8:347-354.
5. Chen, J., and K. Subbarao. 2007. The immunobiology of SARS*. Annu. Rev. Immunol. 25:443-472.
6. de Lang, A., T. Baas, T. Teal, L. M. Leijten, B. Rain, A. D. Osterhaus, B. L. Haagmans, and M. G. Katze. 2007. Functional genomics highlights differential induction of antiviral pathways in the lungs of SARS-CoV-infected macaques. PLoS Pathog. 3:e112.
7. Drosten, C., S. Gunther, W. Preiser, S. van der Werf, H. R. Brodt, S. Becker, H. Rabenau, M. Panning, L. Kolesnikova, R. A. Fouchier, A. Berger, A. M. Burguiere, J. Cinatl, M. Eickmann, N. Escriou, K. Grywna, S. Kramme, J. C. Manuguerra, S. Muller, V. Rickerts, M. Sturmer, S. Vieth, H. D. Klenk, A. D. Osterhaus, H. Schmitz, and H. W. Doerr. 2003. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348:1967-1976.
8. Golda, A., and K. Pyrc. 2008. Recent antiviral strategies against human coronavirus-related respiratory illnesses. Curr. Opin. Pulm. Med. 14:248-253.
9. Gorbalenya, A. E., L. Enjuanes, J. Ziebuhr, and E. J. Snijder. 2006. Nidovirales: evolving the largest RNA virus genome. Virus Res. 117:17-37.
10. Haagmans, B. L., T. Kuiken, B. E. Martina, R. A. Fouchier, G. F. Rimmelzwaan, G. van Amerongen, D. van Riel, T. de Jong, S. Itamura, K. H. Chan, M. Tashiro, and A. D. Osterhaus. 2004. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat. Med. 10:290-293.
11. Han, D. P., M. Lohani, and M. W. Cho. 2007. Specific asparagine-linked glycosylation sites are critical for DC-SIGN- and L-SIGN-mediated severe acute respiratory syndrome coronavirus entry. J. Virol. 81:12029-12039.
12. Jia, H. P., D. C. Look, L. Shi, M. Hickey, L. Pewe, J. Netland, M. Farzan, C. Wohlford-Lenane, S. Perlman, and P. B. McCray, Jr. 2005. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J. Virol. 79:14614-14621.
13. Keyaerts, E., L. Vijgen, C. Pannecouque, E. Van Damme, W. Peumans, H. Egberink, J. Balzarini, and M. Van Ranst. 2007. Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle. Antiviral Res. 75:179-187.
14. Ksiazek, T. G., D. Erdman, C. S. Goldsmith, S. R. Zaki, T. Peret, S. Emery, S. Tong, C. Urbani, J. A. Comer, W. Lim, P. E. Rollin, S. F. Dowell, A. E. Ling, C. D. Humphrey, W. J. Shieh, J. Guarner, C. D. Paddock, P. Rota, B. Fields, J. DeRisi, J. Y. Yang, N. Cox, J. M. Hughes, J. W. LeDuc, W. J. Bellini, and L. J. Anderson. 2003. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348:1953-1966.
15. Li, B. J., Q. Tang, D. Cheng, C. Qin, F. Y. Xie, Q. Wei, J. Xu, Y. Liu, B. J. Zheng, M. C. Woodle, N. Zhong, and P. Y. Lu. 2005. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat. Med. 11:944-951.
16. McCray, P. B., Jr., L. Pewe, C. Wohlford-Lenane, M. Hickey, L. Manzel, L. Shi, J. Netland, H. P. Jia, C. Halabi, C. D. Sigmund, D. K. Meyerholz, P. Kirby, D. C. Look, and S. Perlman. 2007. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J. Virol. 81:813-821.
17. Mori, T., B. R. O'Keefe, R. C. Sowder II, S. Bringans, R. Gardella, S. Berg, P. Cochran, J. A. Turpin, R. W. Buckheit, Jr., J. B. McMahon, and M. R. Boyd. 2005. Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J. Biol. Chem. 280:9345-9353.
18. O'Keefe, B. R., F. Vojdani, V. Buffa, R. J. Shattock, D. C. Montefiori, J. Bakke, J. Mirsalis, A. L. d'Andrea, S. D. Hum., B. Bratcher, C. J. Saucedo, J. B. McMahon, G. P. Pogue, and K. E. Palmer. 2009. Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc. Natl. Acad. Sci. U. S. A. 106:6099-6104.
19. Peiris, J. S., S. T. Lai, L. L. Poon, Y. Guan, L. Y. Yam, W. Lim, J. Nicholls, W. K. Yee, W. W. Yan, M. T. Cheung, V. C. Cheng, K. H. Chan, D. N. Tsang, R. W. Yung, T. K. Ng, and K. Y. Yuen. 2003. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361:1319-1325.
20. Perlman, S., and A. A. Dandekar. 2005. Immunopathogenesis of coronavirus infections: implications for SARS. Nat. Rev. Immunol. 5:917-927.
21. Pyrc, K., B. J. Bosch, B. Berkhout, M. F. Jebbink, R. Dijkman, P. Rottier, and L. van der Hoek. 2006. Inhibition of human coronavirus NL63 infection at early stages of the replication cycle. Antimicrob. Agents Chemother. 50:2000-2008.
22. Ratia, K., S. Pegan, J. Takayama, K. Sleeman, M. Coughlin, S. Baliji, R. Chaudhuri, W. Fu, B. S. Prabhakar, M. E. Johnson, S. C. Baker, A. K. Ghosh, and A. D. Mesecar. 2008. A noncovalent class of papain-like protease/ deubiquitinase inhibitors blocks SARS virus replication. Proc. Natl. Acad. Sci. U. S. A. 105:16119-16124.
23. Roberts, A., D. Deming, C. D. Paddock, A. Cheng, B. Yount, L. Vogel, B. D. Herman, T. Sheahan, M. Heise, G. L. Genrich, S. R. Zaki, R. Baric, and K. Subbarao. 2007. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog. 3:e5.
24. Rockx, B., T. Sheahan, E. Donaldson, J. Harkema, A. Sims, M. Heise, R. Pickles, M. Cameron, D. Kelvin, and R. Baric. 2007. Synthetic reconstruction of zoonotic and early human severe acute respiratory syndrome coronavirus isolates that produce fatal disease in aged mice. J. Virol. 81:7410-7423.
25. Sheahan, T., B. Rockx, E. Donaldson, A. Sims, R. Pickles, D. Corti, and R. Baric. 2008. Mechanisms of zoonotic severe acute respiratory syndrome coronavirus host range expansion in human airway epithelium. J. Virol. 82:2274-2285.
26. Shenoy, S. R., B. R. O'Keefe, A. J. Bolmstedt, L. K. Cartner, and M. R. Boyd. 2001. Selective interactions of the human immunodeficiency virus-inactivating protein cyanovirin-N with high-mannose oligosaccharides on gp120 and other glycoproteins. J. Pharmacol. Exp. Ther. 297:704-710.
27. Sims, A. C., R. S. Baric, B. Yount, S. E. Burkett, P. L. Collins, and R. J. Pickles. 2005. Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs. J. Virol. 79:15511-15524.
28. Smee, D. F., K. W. Bailey, M. H. Wong, B. R. O'Keefe, K. R. Gustafson, V. P. Mishin, and L. V. Gubareva. 2008. Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N. Antiviral Res. 80:266-271.
29. Tong, T. R. 2006. SARS coronavirus anti-infectives. Recent Pat. Antiinfect. Drug Discov. 1:297-308.
30. Tseng, C. T., C. Huang, P. Newman, N. Wang, K. Narayanan, D. M. Watts, S. Makino, M. M. Packard, S. R. Zaki, T. S. Chan, and C. J. Peters. 2007. Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human angiotensin-converting enzyme 2 virus receptor. J. Virol. 81:1162-1173.
31. van der Hoek, L., K. Pyrc, M. F. Jebbink, W. Vermeulen-Oost, R. J. Berkhout, K. C. Wolthers, P. M. Wertheim-van Dillen, J. Kaandorp, J. Spaargaren, and B. Berkhout. 2004. Identification of a new human coronavirus. Nat. Med. 10:368-373.
32. van der Meer, F. J., C. A. de Haan, N. M. Schuurman, B. J. Haijema, W. J. Peumans, E. J. Van Damme, P. L. Delputte, J. Balzarini, and H. F. Egberink. 2007. Antiviral activity of carbohydrate-binding agents against Nidovirales in cell culture. Antiviral Res. 76:21-29.
33. van der Meer, F. J., C. A. de Haan, N. M. Schuurman, B. J. Haijema, M. H. Verheije, B. J. Bosch, J. Balzarini, and H. F. Egberink. 2007. The carbohydrate-binding plant lectins and the non-peptidic antibiotic pradimicin A target the glycans of the coronavirus envelope glycoproteins. J. Antimicrob. Chemother. 60:741-749.
34. Winter, C., G. Herrler, and U. Neumann. 2008. Infection of the tracheal epithelium by infectious bronchitis virus is sialic acid dependent. Microbes Infect. 10:367-373.
35. Wohlford-Lenane, C. L., D. K. Meyerholz, S. Perlman, H. Zhou, D. Tran, M. E. Selsted, and P. B. McCray, Jr. 2009. Rhesus theta-defensin prevents death in a mouse model of severe acute respiratory syndrome coronavirus pulmonary disease. J. Virol. 83:11385-11390.
36. Woo, P. C., S. K. Lau, C. M. Chu, K. H. Chan, H. W. Tsoi, Y. Huang, B. H. Wong, R. W. Poon, J. J. Cai, W. K. Luk, L. L. Poon, S. S. Wong, Y. Guan, J. S. Peiris, and K. Y. Yuen. 2005. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J. Virol. 79:884-895.
37. Ziolkowska, N. E., B. R. O'Keefe, T. Mori, C. Zhu, B. Giomarelli, F. Vojdani, K. E. Palmer, J. B. McMahon, and A. Wlodawer. 2006. Domain-swapped structure of the potent antiviral protein griffithsin and its mode of carbohydrate binding. Structure 14:1127-1135.
38. Ziolkowska, N. E., S. R. Shenoy, B. R. O'Keefe, J. B. McMahon, K. E. Palmer, R. A. Dwek, M. R. Wormald, and A. Wlodawer. 2007. Crystallographic, thermodynamic, and molecular modeling studies of the mode of binding of oligosaccharides to the potent antiviral protein griffithsin. Proteins 67:661-670.